拉泽替尼对比吉非替尼一线治疗EGFR突变晚期非小细胞肺癌:LASER301研究亚洲亚组分析
LASER301研究的亚洲亚组分析纳入258例EGFR突变晚期非小细胞肺癌初治患者,随机接受拉泽替尼或吉非替尼治疗。拉泽替尼组中位无进展生存期显著长于吉非替尼组(20.6个月 vs 9.7个月;HR 0.46;95%CI 0.34-0.63,p<0.001),客观缓解率和疾病控制率两组相似,安全性特征与总体人群一致。
要点
- 亚洲EGFR突变晚期NSCLC初治患者中,拉泽替尼中位PFS为20.6个月,吉非替尼为9.7个月(HR 0.46)。
- 预设亚组(外显子19缺失、L858R、基线中枢神经系统转移)中拉泽替尼获益一致。
- 两组客观缓解率和疾病控制率相似,导致停药的不良事件发生率拉泽替尼组13%、吉非替尼组12%。
核心结论
- 在LASER301研究的亚洲患者中,拉泽替尼的疗效与安全性结果与总体人群一致。
- 拉泽替尼在亚洲患者中较吉非替尼显示出更好的疗效,且安全性可耐受。
研究设计与样本
- LASER301是一项3期研究,评估拉泽替尼在EGFR突变(外显子19缺失或L858R)局部晚期或转移性NSCLC初治患者中的疗效与安全性。
- 患者按1:1随机接受拉泽替尼或吉非替尼治疗;本次分析纳入258例亚洲裔患者,时间为2020年2月13日至2022年7月29日。
- 主要终点为研究者依据RECIST 1.1评估的无进展生存期;次要终点包括总生存期、客观缓解率、缓解持续时间和安全性。
主要发现
- 拉泽替尼组中位无进展生存期为20.6个月,吉非替尼组为9.7个月(HR 0.46;95%CI 0.34-0.63;p<0.001)。
- 在预设亚组(外显子19缺失、L858R、基线中枢神经系统转移)中,拉泽替尼的获益一致。
- 两组客观缓解率和疾病控制率相似。
- 拉泽替尼组中位缓解持续时间为19.4个月(95%CI 16.6-24.9),吉非替尼组为9.6个月(95%CI 6.9-12.4)。
- 亚洲患者的不良事件发生率与LASER301总体人群相当;导致停药的不良事件在拉泽替尼组为13%,吉非替尼组为12%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lazertinib is a third-generation central nervous system-penetrant tyrosine kinase inhibitor targeting mutant EGFR in NSCLC. Lazertinib exhibited improved efficacy versus gefitinib in the LASER301 study; this subset analysis compared lazertinib with gefitinib among Asian patients. METHODS: The phase 3 LASER301 study evaluated lazertinib efficacy and safety in treatment-naive patients with EGFR-mutated (exon 19 deletion or L858R) locally advanced or metastatic NSCLC. Patients were randomized one-to-one and received either lazertinib or gefitinib. The primary end point was investigator-assessed progression-free survival using Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included overall survival, objective response rate, duration of response, and safety. RESULTS: Between February 13, 2020, and July 29, 2022, among 258 patients of Asian descent, the median progression-free survival was significantly longer with lazertinib than gefitinib (20.6 versus 9.7 mo; hazard ratio: 0.46; 95% confidence interval [CI]: 0.34-0.63, p < 0.001), and the benefit was consistent across predefined subgroups (exon 19 deletion, L858R, baseline central nervous system metastases). Objective response rate and disease control rates were similar between treatment groups. The median duration of response was 19.4 months (95% CI: 16.6-24.9) versus 9.6 months (95% CI: 6.9-12.4) in the lazertinib versus gefitinib group. Adverse event rates in Asian patients were comparable with the overall LASER301 population. Adverse events leading to discontinuation in the lazertinib and gefitinib groups were 13% and 12%, respectively. CONCLUSIONS: In LASER301, efficacy and safety results in Asian patients were consistent with the overall population. Lazertinib exhibited better efficacy than gefitinib in Asian patients with a tolerable safety profile.
引用
- Reungwetwattana T, Cho BC, Lee KH, et al. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301. J Thorac Oncol. 2023. PMID: 37702629. doi:10.1016/j.jtho.2023.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。